Explore

Trendline Trendline
Novastra Therapeutics Appoints New CFO Amid Global Clinical Development Efforts

Novastra Therapeutics Appoints New CFO Amid Global Clinical Development Efforts

Novastra Therapeutics Appoints New CFO Amid Global Clinical Development Efforts
Trendline Trendline
Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development

Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development

Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development
Trendline Trendline
Parabilis Medicines and Regeneron Pharmaceuticals Collaborate on Novel Therapeutics

Parabilis Medicines and Regeneron Pharmaceuticals Collaborate on Novel Therapeutics

Parabilis Medicines and Regeneron Pharmaceuticals Collaborate on Novel Therapeutics
Trendline Trendline
Parabilis and Regeneron Partner to Develop Novel Antibody-Helicon Conjugates

Parabilis and Regeneron Partner to Develop Novel Antibody-Helicon Conjugates

Parabilis and Regeneron Partner to Develop Novel Antibody-Helicon Conjugates
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment with PIKTOR Amid Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment with PIKTOR Amid Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment with PIKTOR Amid Financial Growth
Trendline Trendline
Regeneron's Fianlimab Fails Phase 3 Melanoma Trial, Impacting Market Prospects

Regeneron's Fianlimab Fails Phase 3 Melanoma Trial, Impacting Market Prospects

Regeneron's Fianlimab Fails Phase 3 Melanoma Trial, Impacting Market Prospects
Trendline Trendline
Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement
Trendline Trendline
Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success

Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success

Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success
Trendline Trendline
Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase
Trendline Trendline
Faruqi Faruqi, LLP Alerts Immutep Investors of Securities Class Action Deadline

Faruqi Faruqi, LLP Alerts Immutep Investors of Securities Class Action Deadline

Faruqi Faruqi, LLP Alerts Immutep Investors of Securities Class Action Deadline
Trendline Trendline
Citius Oncology Secures $36.5 Million Financing Amid LYMPHIR Launch Progress

Citius Oncology Secures $36.5 Million Financing Amid LYMPHIR Launch Progress

Citius Oncology Secures $36.5 Million Financing Amid LYMPHIR Launch Progress